Related Experiment Video

Updated: Aug 13, 2026

A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction
03:42

A Murine Model of Hyperlipidemia-Induced Heart Failure with Preserved Ejection Fraction

Published on: March 29, 2024

Advances in Cardiovascular Pharmacotherapy. X. Glucagon-Like Peptide-1 Receptor Agonists in Heart Failure and

Paul S Pagel1, Dustin Hang1, Julie K Freed1

  • 1Department of Anesthesiology, Medical College of Wisconsin, Milwaukee, WI.

Journal of Cardiothoracic and Vascular Anesthesia
|August 11, 2026
PubMed

Insights

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) improve heart failure symptoms and quality of life in patients with preserved ejection fraction. These GLP-1 RAs also offer cardiovascular protection through various mechanisms.

Area of Science:

  • Cardiology
  • Endocrinology
  • Pharmacology

Background:

  • Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated cardiovascular benefits in patients with type 2 diabetes and atherosclerotic cardiovascular disease.
  • Recent evidence suggests GLP-1 RAs may also impact heart failure management.

Purpose of the Study:

  • To review recent clinical trials on the effects of GLP-1 RAs in patients with heart failure.
  • To discuss the mechanisms underlying the cardiovascular protective effects of GLP-1 RAs in atherosclerotic cardiovascular disease and heart failure.

Main Methods:

  • Review of recent clinical trials and substudies.
  • Analysis of evidence for cardiovascular protection and effects on heart failure symptoms and exercise tolerance.

Main Results:

  • GLP-1 RAs reduce symptom burden, increase exercise tolerance, and improve quality of life in heart failure with preserved ejection fraction (HFpEF).
  • These benefits were not observed in heart failure with reduced ejection fraction (HFrEF).
  • Mechanisms for cardiovascular protection in atherosclerotic cardiovascular disease and heart failure are discussed.

Conclusions:

  • GLP-1 RAs show promise in managing HFpEF, improving patient-reported outcomes and exercise capacity.
  • Understanding the mechanisms of cardiovascular protection is crucial for optimizing therapeutic strategies.
Keywords:
GLP-1 receptor agonistsHFpEFHFrEFMACEobesitytype 2 diabetes

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...